Pharmacokinetics of di-n-propylacetate in epileptic patients

No abstract is available for this paper.

• Publication year

  1975

• Venue

  European Journal of Clinical Pharmacology

• Publication date

  1975-02-28

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/BF00561557PMID 786678
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A formula to estimate the approximate surface area if height and weight be known

  1989cited by this paper
• Action de l'Acide Dipropylacétique Chez le Papio papio Photosensible

  1971cited by this paper
• Clinical trials of anti-epileptic drugs.

  1971cited by this paper
• Biopharmaceutics and Relevant Pharmacokinetics

  1971cited by this paper
• [Action of dipropylacetic acid upon photosensitive Papio papio].

  1971cited by this paper
• Klinische Erfahrungen mit einem neuen Antiepileptikum: Dipropylessigsäure

  1971cited by this paper
• [Clinical experiences with a new antiepileptic agent: dipropyl-acetic acid].

  1971cited by this paper
• [Depakine in the treatment of essential or idiopathic epilepsy].

  1970cited by this paper
• EFFECTS OF DI‐n‐PROPYLACETATE, AN ANTICONVULSIVE COMPOUND, ON GABA METABOLISM 1

  1969cited by this paper
• [Effects of di-n-propylacetate on audiogenic crises in mice].

  1968cited by this paper
• [PHARMACODYNAMIC PROPERTIES OF 2,2-DIPROPYLACETIC ACID. 2D REPORT ON ITS ANTI-EPILEPTIC PROPERTIES].

  1964cited by this paper
• DIPHENYLHYDANTOIN AND PHENOBARBITAL. SERUM LEVELS IN CHILDREN.

  1964cited by this paper
• CLINICAL CALORIMETRY: TENTH PAPER A FORMULA TO ESTIMATE THE APPROXIMATE SURFACE AREA IF HEIGHT AND WEIGHT BE KNOWN

  1916cited by this paper

• Association of Valproic Acid and Its Main Metabolites’ Plasma Concentrations with Clinical Outcomes among Epilepsy Patients: A 10-Year Retrospective Study Based on Therapeutic Drug Monitoring

  2024cites this paper
• SARS-CoV-2 Infection, Sex-Related Differences, and a Possible Personalized Treatment Approach with Valproic Acid: A Review

  2022cites this paper
• Switching Between LC-ESI-MS/MS and EMIT Methods for Routine TDM of Valproic Acid in Pediatric Patients With Epilepsy: What Clinicians and Researchers Need to Know

  2021influential citation
• Chronic Valproic Acid Administration Increases Plasma, Liver, and Brain Ammonia Concentration and Suppresses Glutamine Synthetase Activity

  2020cites this paper
• Exploring the Drug Repurposing Versatility of Valproic Acid as a Multifunctional Regulator of Innate and Adaptive Immune Cells

  2019cites this paper
• Determinants of free serum valproate concentration: A prospective study in patients on divalproex sodium monotherapy.

  2018cites this paper
• Physiologically based pharmacokinetic modeling of disposition and drug‐drug interactions for valproic acid and divalproex

  2018cites this paper
• The Effect of Uridine Diphosphate Glucuronosyltransferase (UGT)1A6 Genetic Polymorphism on Valproic Acid Pharmacokinetics in Indian Patients with Epilepsy: A Pharmacogenetic Approach

  2013cites this paper
• Methodological aspects of the evaluation of the binding of drugs to plasma and tissue proteins

  2010cites this paper
• Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy.

  2009cites this paper
• Valproic Acid : Review Ácido Valpróico : revisão Sayonara

  2009cites this paper
• Hyperammonemia and hepatic status during valproate therapy

  2009cites this paper
• Ácido Valpróico: revisão

  2008cites this paper
• Population Pharmacokinetics of Valproic Acid Concentrations in Elderly Nursing Home Residents

  2007cites this paper
• Therefore forced acid diuresis could be recommended to enhance both the elimination of chloroquine and its more water soluble metabolites

  2006cites this paper
• On the TRAIL of a new therapy for leukemia

  2005cites this paper
• Enzyme cytochemistry combined with electron microscopy, pharmacokinetics, and clinical chemistry for the evaluation of the effects of steady-state valproic acid concentrations on the mouse

  2004cites this paper
• Plasma concentrations of valproate during maintenance therapy in epileptic children

  2004cites this paper
• Pharmacokinetics of sodium valproate in epileptic patients: Prediction of maintenance dosage by single-dose study

  2004cites this paper
• The effects of peritoneal dialysis on the single dose and steady state pharmacokinetics of valproic acid in a uremic epileptic child

  2004cites this paper
• Population pharmacokinetics of intravenous valproic acid in Korean patients

  2002cites this paper
• Therapeutic drug monitoring--antiepileptic drugs.

  2001cites this paper
• Investigation of Phenobarbital-Carbamazepine-Valproic Acid Interactions using Population Pharmacokinetic Analysis for Optimisation of Antiepileptic Drug Therapy: An Overview

  2000cites this paper
• Anticonvulsant Blood Levels: Historical Review With a Pediatric Focus

  2000cites this paper
• Study on the dose proportionality of the pharmacokinetics of sustained release sodium valproate.

  2000cites this paper
• Population‐based investigations of drug relative clearance using nonlinear mixed‐effect modelling from information generated during the routine clinical careof patients

  1999cites this paper
• Detection of Carbamazepine‐induced Changes in Valproic Acid Relative Clearance in Man by Simple Pharmacokinetic Screening

  1997cites this paper
• Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial. Depakote Monotherapy for Partial Seizures Study Group.

  1997cites this paper
• Reduction in blood free carnitine levels in association with changes in sodium valproate (VPA) disposition in epileptic patients treated with VPA and other anti-epileptic drugs.

  1997cites this paper
• Asymptomatic Hyperammonemia in Children Treated With Valproic Acid

  1997cites this paper
• Population‐Based Investigation of Valproic Acid Relative Clearance Using Nonlinear Mixed Effects Modeling: Influence of Drug‐Drug Interaction and Patient Characteristics

  1997cites this paper
• Pharmacokinetic Interactions Between Antiepileptic Drugs

  1996cites this paper
• Clinical Pharmacokinetics of Antiepileptic Drugs in Paediatric Patients

  1995cites this paper
• A Feasibility Study of the Multiple‐peak Approach for Pharmacokinetic Screening: Population‐based Investigation of Valproic Acid Relative Clearance Using Routine Clinical Pharmacokinetic Data

  1995cites this paper
• A Model for Estimating Individualized Valproate Clearance Values in Children

  1995cites this paper
• Effects of the anticonvulsant, valproate, on the expression of components of the cytochrome-P-450-mediated monooxygenase system and glutathione S-transferases.

  1995cites this paper
• Inhibition of phenobarbitone N-glucosidation by valproate.

  1994cites this paper
• Disposition and protein binding of valproic acid in the developing rat.

  1994cites this paper
• The effect of felbamate on valproic acid disposition

  1994cites this paper
• Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy.

  1994cites this paper
• Antiepileptic medication interactions.

  1993cites this paper
• Valproate and palmitate binding to serum albumin in valproate-treated patients. Relation to obesity.

  1993cites this paper
• Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance

  1993cites this paper
• Pharmacokinetics of valproate in pregnancy: Mother-foetus-newborn

  1992cites this paper
• Relationship Between Serum Concentration and Dose of Valproic Acid During Monotherapy in Adult Outpatients

  1992cites this paper
• A comparative clinical and pharmacokinetic study of a new slow-release versus conventional preparations of valproic acid in children with intractable epilepsy.

  1992cites this paper
• Chemical systems for delivery of antiepileptic drugs to the central nervous system.

  1992cites this paper
• The effect of carnitine on the metabolism of valproic acid in epileptic patients.

  1992cites this paper
• Formation of Active Metabolites of Anticonvulsant Drugs

  1991cites this paper
• INFLUENCE OF AGE AND CONCURRENT MEDICATION ON STEADY‐STATE VALPROIC ACID SERUM LEVEL‐DOSE RATIOS IN JAPANESE PAEDIATRIC PATIENTS

  1991cites this paper
• Effects of administration route on valproate pharmacokinetics in the rabbit

  1991cites this paper
• The inducing and inhibiting effects of sodium valproate in vivo on the biotransformation systems of xenobiotics in isolated rat hepatocytes.

  1988cites this paper
• Serum valproate concentrations in epileptic children with favourable responses.

  1987cites this paper
• Factors which influence the effectiveness of treatment of epilepsy.

  1986cites this paper
• Antiepileptic drug toxicity: Definition and mechanism of action

  1986cites this paper
• Adverse effects of anticonvulsant drugs--a critical review.

  1986cites this paper
• Therapeutic drug monitoring in childhood

  1986cites this paper
• Effect of Sodium Valproate on Phenobarbital Serum Levels in Children and Adults

  1986cites this paper
• Therapeutic drug monitoring

  1986cites this paper
• An Update on Sodium Valproate

  1985cites this paper
• Concentration-Effect Relationships of Valproic Acid

  1985cites this paper
• Valproic acid pharmacokinetics in children. II.

  1985cites this paper
• Distribution of sodium valproate and GABA metabolism in CNS of the rat.

  1984cites this paper
• Variability in Level‐Dose Ratio of Valproate: Monotherapy Versus Polytherapy

  1984cites this paper
• Open Trials with Valproate in Epilepsy

  1984cites this paper
• Anticonvulsant Drugs

  1984cites this paper
• Epilepsy: 2. Treatment

  1984cites this paper
• Rectal administration of sodium valproate in children

  1984cites this paper
• Plasma concentrations of sodium valproate: Their clinical value

  1983cites this paper
• First-Dose and Steady-State Pharmacokinetics of Valproic Acid in Children with Seizures

  1983cites this paper
• Intra-daily oscillations in dipropylacetic acid plasma levels with two or three daily doses of dipropylacetamide in epileptic patients

  1983cites this paper
• Bioavailability of Calcium Valproate in Normal Men Compared with the Free Acid and Sodium Salt

  1983cites this paper
• The effects of valproate on intermediary metabolism in isolated rat hepatocytes and intact rats.

  1983cites this paper
• Pharmacokinetics of valproic acid in children: I. Multiple antiepileptic drug therapy.

  1983cites this paper
• Transplacental passage and half-life of sodium valproate in infants born to epileptic mothers.

  1983cites this paper
• Lack of cross-reactivity between EMIT valproic acid assay and N-dipropylacetamide.

  1983cites this paper
• [Pharmacokinetic elements of sodium valproate. Use in febrile convulsions in children].

  1983cites this paper
• Valproic Acid: Interactions with Phenytoin and Phenobarbital

  1982cites this paper
• In vivo uptake of valproic acid into brain.

  1982cites this paper
• The Pharmacokinetics of Valproic Acid After Oral and Parenteral Administration in Healthy Volunteers

  1982cites this paper
• Rapid and simple GLC determination of valproic acid and ethosuximide in plasma of epileptic patients.

  1982cites this paper
• Clinical and pharmacokinetic observations on sodium valproate – A 5‐year follow‐up study in 100 children with epilepsy

  1982cites this paper
• Bioavailability of a slow-release preparation of valproic acid under steady-state conditions.

  1982cites this paper
• Free sodium valproate monitoring.

  1982cites this paper
• Plasma Levels of Sodium Valproate in Childhood Epilepsy

  1982cites this paper
• Mechanism of anticonvulsant action of valproate

  1982cites this paper
• Diurnal Variations in Steady-state Plasma Concentrations of Valproic Acid in Epileptic Patients

  1982cites this paper
• Drug Interactions with Valproic Acid

  1982cites this paper
• Phenobarbital, primidone and sodium valproate in the prophylaxis of febrile convulsions.

  1981cites this paper
• Comparison of Sodium Valproate and Phenytoin as Single Drug Treatment in Epilepsy

  1981cites this paper
• Reduction of Steady‐State Valproate Levels by Other Antiepileptic Drugs

  1981cites this paper
• Antiepileptic drugs: pharmacokinetic and clinical aspects.

  1981cites this paper
• Dipropylacetic acid plasma levels; diurnal fluctuations during chronic treatment with dipropylacetamide.

  1981cites this paper
• Chronic valproate administration produces hepatic dysfunction and may delay brain maturation in infant mice

  1981cites this paper
• Human brain, plasma, and cerebrospinal fluid concentration of sodium valproate after 72 hours of therapy.

  1981cites this paper
• Bioavailability of rectally administered valproic acid syrup

  1981cites this paper
• Serum protein binding of valproic acid in healthy subjects and in patients with liver disease.

  1981cites this paper
• Plasma levels and pharmacokinetics of antipileptic drugs in children.

  1981cites this paper
• Effects of food on valproic acid absorption.

  1981cites this paper
• [Effect of valproate monotherapy on spike-wave activity in generalized epilepsies (author's transl)].

  1981cites this paper